[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Bios S.r.l.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":97},{"warningLetters":4,"total":96},[5,31,52,74],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},3126,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2021-10-05T13:20:00Z\">10\u002F05\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-22T04:00:00Z\">09\u002F22\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fardil-comercial-srl-612018-09222021\">Ardil Comercial S.R.L.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Cecilia Ramirez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Administrative Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Ardil Comercial S.R.L.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Pastora Elida Km 19 No. 03, Apto. 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>11606\u003C\u002Fspan> \u003Cspan>Santo Domingo\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dominican Republic\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-21-59\u003C\u002Fp>\n\n\u003Cp>September 22, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Ramirez:\u003C\u002Fp>\n\n\u003Cp>Your firm registered as a human drug manufacturer. The United States Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer), labeled as Alcohol Isopropilico Hand Sanitizer Limar. This drug product was labeled as manufactured at your facility, Ardil Comercial S.R.L., FEI 3012644697, at Pastora Elida Km 19 No. 03, Apto. 1, Santo Domingo, 11606, Dominican Republic. Following an attempt to import Alcohol Isopropilico Hand Sanitizer Limar into the United States, it was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of a batch of this product detained at the border demonstrate that this drug product labeled as manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, Alcohol Isopropilico Hand Sanitizer Limar is an unapproved new drug in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(a), (c), (i)(1), (x) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a), (c), (i)(1), (x) and (ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Alcohol Isopropilico Hand Sanitizer Limar, labeled as manufactured at your facility, is labeled to contain 70% of the active ingredient Isopropyl Alcohol (IPA). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average of 48% IPA volume\u002Fvolume (v\u002Fv), and an average of 16% ethanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient, IPA, was substituted wholly or in part with undeclared ethanol.\u003C\u002Fp>\n\n\u003Cp>On February 23, 2021, FDA held a teleconference with you and Registrar Corp, your registered U.S. Agent. During the call, we requested additional information concerning your CGMP operations, including test methods for your incoming active pharmaceutical ingredient, IPA, and finished product. As noted above, your hand sanitizer product labeled to contain IPA also contained ethanol. We requested information related to the investigation into how your hand sanitizer drug product was manufactured with a mixture of both IPA and ethanol. You acknowledged you were aware that the product was mislabeled and shipped to the United States. Following the teleconference, FDA sent multiple requests to your firm to provide additional information. Your firm has since exhibited a pattern of not providing adequate or complete responses to FDA’s requests for information regarding drug quality. In your response, you did not provide test methods for your incoming API or finished product to ensure appropriate identity test for IPA, as required under 21 CFR 211.84 and appropriate assay testing for finished product as required per 21 CFR 211.165. Without adequate testing of incoming raw materials and finished product you cannot assure that your drug products conform to appropriate standards of identity, strength, quality and purity. Your investigation provided lacked detailed information, including specific lot information.\u003C\u002Fp>\n\n\u003Cp>On June 16, 2021, FDA held a second teleconference with you and Registrar Corp, your registered U.S. Agent to express concerns regarding your Alcohol Isopropilico Hand Sanitizer Limar packaged in a container that resembles a water bottle or beverage\u002Fdrink container, commonly used by adults and children in the U.S. market. This hand sanitizer container has a similar shape, size, and function as a water bottle and can mislead children or adults into believing that the product is consumable water, which is of particular concern because hand sanitizers can be toxic if ingested. We recommended you consider removing lot 079932-4611-05-J of your hand sanitizer drug product distributed to the U.S. market. On June 16, 2021, FDA notified the public of your hand sanitizer drug product packaged in containers resembling a water bottle that presents increased risk of accidental ingestion at the following website:\u003Cbr>\n\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>On July 1, 2021, you issued a voluntary nationwide recall of one lot of Alcohol Isopropilico Hand Sanitizer Limar due to the hand sanitizer packaged in bottles that resemble drink containers, as noted on the following FDA website:\u003Cbr>\n\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fardil-comercial-issues-voluntary-nationwide-recall-limar-hand-sanitizer-packaged-4-oz-bottles?utm_medium=email&amp;utm_source=govdelivery\">https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fardil-comercial-issues-voluntary-nationwide-recall-limar-hand-sanitizer-packaged-4-oz-bottles?utm_medium=email&amp;utm_source=govdelivery\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003Cbr>\n\u003Cbr>\n• An updated investigation into how the drug product described above, which was labeled as manufactured at your facility and which was labeled as containing IPA, was substituted in part with ethanol.\u003Cbr>\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products shipped to the U.S. by your firm, and a full reconciliation of all material you distributed.\u003Cbr>\n• Copies of the complete batch records for all batches distributed to the United States.\u003Cbr>\n• Provide a commitment that you will test every lot of IPA and ethanol you receive for methanol content using the United States Pharmacopeia (USP) method in a CGMP compliant laboratory.\u003C\u002Fp>\n\n\u003Cp>The substitution of hand sanitizer drug product labeled as manufactured in your facility, in addition to the deficiencies in your response to the information we requested during the June 16, 2021 teleconference, demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Alcohol Isopropilico Hand Sanitizer Limar is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the Alcohol Isopropilico Hand Sanitizer Limar product label and labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“Antibacterial . . . Drug Facts . . . Antimicrobial Uses hand sanitizer to help reduce bacteria on the skin”\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling.\u003C\u002Fp>\n\n\u003Cp>New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below). No FDA approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your Alcohol Isopropilico Hand Sanitizer Limar drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>According to the product label, Alcohol Isopropilico Hand Sanitizer Limar purportedly contains the active ingredient isopropyl alcohol 70%. However, as previously discussed, FDA laboratory analyses of a batch of this product detained at the border demonstrated that Alcohol Isopropilico Hand Sanitizer Limar contains isopropyl alcohol in a concentration that is less than the 70% stated on its product label and less than the amount of isopropyl alcohol described in the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Furthermore, the analyses revealed that the product contained concentrations of the undeclared ingredient, ethanol. Ethanol as a sole active ingredient, is permitted for use in a consumer topical antiseptic rub. However, ethanol in combination with isopropyl alcohol was not proposed for use as consumer drug products. Further, even if ethanol was intended to be the only active ingredient for the product, the concentrations of the undeclared ingredient is below the concentration allowed under the TFM. Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, Alcohol Isopropilico Hand Sanitizer Limar is misbranded under sections 502(a), (c), (i)(1), (x) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(a), (c), (i)(1), (x) and (ee).\u003C\u002Fp>\n\n\u003Cp>It is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), because its labeling is false or misleading. As noted above, Alcohol Isopropilico Hand Sanitizer Limar is labeled to contain isopropyl alcohol 70% v\u002Fv. However, FDA laboratory analysis of batch of this product demonstrate that the product contains concentrations of isopropyl alcohol less than that stated on its product label but contains ethanol even though the product label does not include ethanol as an ingredient. Thus, the misleading representations of the concentration of the active ingredient isopropyl alcohol on the Alcohol Isopropilico Hand Sanitizer Limar labeling cause this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>Alcohol Isopropilico Hand Sanitizer Limar contains labeling information both in English and Spanish. Dual language labeling with English and another language is permissible when labeled in accordance to 21 CFR 201.15 and not otherwise false or misleading. Please note, 21 CFR 201.15 states that “all words, statements, and other information required by or under authority of the act to appear on the label or labeling shall appear thereon in the English language” . . . and “if the label contains any representation in a foreign language, all words, statements, and other information required by or under authority of the act to appear on the label shall appear thereon in the foreign language.” The labeling for Alcohol Isopropilico Hand Sanitizer Limar is misbranded under section 502(c) of the FD&amp;C Act, 21 U.S.C. 352(c), because it is not labeled in accordance to 21 CFR 201.15. For example, the label does not include a “Drug Facts” panel in the Spanish language.\u003C\u002Fp>\n\n\u003Cp>Alcohol Isopropilico Hand Sanitizer Limar is in a 4 fluid ounce container that resembles a drinking water bottle customarily purchased by U.S. consumers. Section 502(i)(1) of the FD&amp;C Act, 21 U.S.C. 352(i)(1), provides that a drug is misbranded if “its container is so made, formed, or filled as to be misleading . . .” As such, your clear, colorless hand sanitizer that fills a 4 fluid ounce container resembling plastic bottles ordinarily used to package drinking water is misbranded under section 502(i)(1) of the FD&amp;C Act, 21 U.S.C. 352(i)(1).\u003C\u002Fp>\n\n\u003Cp>Alcohol Isopropilico Hand Sanitizer Limar is misbranded under section 502(x) of the FD&amp;C Act, 21 U.S.C. 352(x), because the product label fails to disclose a domestic address or domestic telephone number through which the responsible person may receive a report of a serious adverse event with such drug.\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because Alcohol Isopropilico Hand Sanitizer Limar is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on June 30, 2021, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&amp;C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with FEI 3012644697 and ATTN: Tamara Rosbury.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nRegistered U.S. Agent\u003Cbr>\nRegistrar Corp\u003Cbr>\n144 Research Drive\u003Cbr>\nHampton, VA 23666\u003Cbr>\nUSA\u003C\u002Fp>\n\n\u003Cp>________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution of hand sanitizer products manufactured at your facility, a review of the purported formulations on the drug products’ labeling further indicates that such products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution. 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because Alcohol Isopropilico Hand Sanitizer Limar is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Cecilia Ramirez\n\nRecipient Title\n\nAdministrative Director\n\nArdil Comercial S.R.L.\n\nPastora Elida Km 19 No. 03, Apto. 1\n\n11606 Santo Domingo\n\nDominican Republic\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-59\n\nSeptember 22, 2021\n\nDear Ms. Ramirez:\n\nYour firm registered as a human drug manufacturer. The United States Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer), labeled as Alcohol Isopropilico Hand Sanitizer Limar. This drug product was labeled as manufactured at your facility, Ardil Comercial S.R.L., FEI 3012644697, at Pastora Elida Km 19 No. 03, Apto. 1, Santo Domingo, 11606, Dominican Republic. Following an attempt to import Alcohol Isopropilico Hand Sanitizer Limar into the United States, it was detained and refused admission at the border.\n\nThe results of the FDA laboratory testing of a batch of this product detained at the border demonstrate that this drug product labeled as manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, Alcohol Isopropilico Hand Sanitizer Limar is an unapproved new drug in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(a), (c), (i)(1), (x) and (ee) of the FD&C Act, 21 U.S.C. 352(a), (c), (i)(1), (x) and (ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nAdulteration Violations\n\nAlcohol Isopropilico Hand Sanitizer Limar, labeled as manufactured at your facility, is labeled to contain 70% of the active ingredient Isopropyl Alcohol (IPA). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average of 48% IPA volume\u002Fvolume (v\u002Fv), and an average of 16% ethanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient, IPA, was substituted wholly or in part with undeclared ethanol.\n\nOn February 23, 2021, FDA held a teleconference with you and Registrar Corp, your registered U.S. Agent. During the call, we requested additional information concerning your CGMP operations, including test methods for your incoming active pharmaceutical ingredient, IPA, and finished product. As noted above, your hand sanitizer product labeled to contain IPA also contained ethanol. We requested information related to the investigation into how your hand sanitizer drug product was manufactured with a mixture of both IPA and ethanol. You acknowledged you were aware that the product was mislabeled and shipped to the United States. Following the teleconference, FDA sent multiple requests to your firm to provide additional information. Your firm has since exhibited a pattern of not providing adequate or complete responses to FDA’s requests for information regarding drug quality. In your response, you did not provide test methods for your incoming API or finished product to ensure appropriate identity test for IPA, as required under 21 CFR 211.84 and appropriate assay testing for finished product as required per 21 CFR 211.165. Without adequate testing of incoming raw materials and finished product you cannot assure that your drug products conform to appropriate standards of identity, strength, quality and purity. Your investigation provided lacked detailed information, including specific lot information.\n\nOn June 16, 2021, FDA held a second teleconference with you and Registrar Corp, your registered U.S. Agent to express concerns regarding your Alcohol Isopropilico Hand Sanitizer Limar packaged in a container that resembles a water bottle or beverage\u002Fdrink container, commonly used by adults and children in the U.S. market. This hand sanitizer container has a similar shape, size, and function as a water bottle and can mislead children or adults into believing that the product is consumable water, which is of particular concern because hand sanitizers can be toxic if ingested. We recommended you consider removing lot 079932-4611-05-J of your hand sanitizer drug product distributed to the U.S. market. On June 16, 2021, FDA notified the public of your hand sanitizer drug product packaged in containers resembling a water bottle that presents increased risk of accidental ingestion at the following website:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nOn July 1, 2021, you issued a voluntary nationwide recall of one lot of Alcohol Isopropilico Hand Sanitizer Limar due to the hand sanitizer packaged in bottles that resemble drink containers, as noted on the following FDA website:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fardil-comercial-issues-voluntary-nationwide-recall-limar-hand-sanitizer-packaged-4-oz-bottles?utm_medium=email&utm_source=govdelivery\n\nIn response to this letter, provide the following:\n\n• An updated investigation into how the drug product described above, which was labeled as manufactured at your facility and which was labeled as containing IPA, was substituted in part with ethanol.\n\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\n• A list of all batches of any hand sanitizer drug products shipped to the U.S. by your firm, and a full reconciliation of all material you distributed.\n\n• Copies of the complete batch records for all batches distributed to the United States.\n\n• Provide a commitment that you will test every lot of IPA and ethanol you receive for methanol content using the United States Pharmacopeia (USP) method in a CGMP compliant laboratory.\n\nThe substitution of hand sanitizer drug product labeled as manufactured in your facility, in addition to the deficiencies in your response to the information we requested during the June 16, 2021 teleconference, demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.1\n\nUnapproved New Drug and Misbranding Violations\n\nAlcohol Isopropilico Hand Sanitizer Limar is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic.\n\nExamples of claims observed on the Alcohol Isopropilico Hand Sanitizer Limar product label and labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“Antibacterial . . . Drug Facts . . . Antimicrobial Uses hand sanitizer to help reduce bacteria on the skin”\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling.\n\nNew drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below). No FDA approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your Alcohol Isopropilico Hand Sanitizer Limar drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nAccording to the product label, Alcohol Isopropilico Hand Sanitizer Limar purportedly contains the active ingredient isopropyl alcohol 70%. However, as previously discussed, FDA laboratory analyses of a batch of this product detained at the border demonstrated that Alcohol Isopropilico Hand Sanitizer Limar contains isopropyl alcohol in a concentration that is less than the 70% stated on its product label and less than the amount of isopropyl alcohol described in the 1994 TFM.2 Furthermore, the analyses revealed that the product contained concentrations of the undeclared ingredient, ethanol. Ethanol as a sole active ingredient, is permitted for use in a consumer topical antiseptic rub. However, ethanol in combination with isopropyl alcohol was not proposed for use as consumer drug products. Further, even if ethanol was intended to be the only active ingredient for the product, the concentrations of the undeclared ingredient is below the concentration allowed under the TFM. Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.3\n\nAdditionally, Alcohol Isopropilico Hand Sanitizer Limar is misbranded under sections 502(a), (c), (i)(1), (x) and (ee) of the FD&C Act, 21 U.S.C. 352(a), (c), (i)(1), (x) and (ee).\n\nIt is misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), because its labeling is false or misleading. As noted above, Alcohol Isopropilico Hand Sanitizer Limar is labeled to contain isopropyl alcohol 70% v\u002Fv. However, FDA laboratory analysis of batch of this product demonstrate that the product contains concentrations of isopropyl alcohol less than that stated on its product label but contains ethanol even though the product label does not include ethanol as an ingredient. Thus, the misleading representations of the concentration of the active ingredient isopropyl alcohol on the Alcohol Isopropilico Hand Sanitizer Limar labeling cause this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nAlcohol Isopropilico Hand Sanitizer Limar contains labeling information both in English and Spanish. Dual language labeling with English and another language is permissible when labeled in accordance to 21 CFR 201.15 and not otherwise false or misleading. Please note, 21 CFR 201.15 states that “all words, statements, and other information required by or under authority of the act to appear on the label or labeling shall appear thereon in the English language” . . . and “if the label contains any representation in a foreign language, all words, statements, and other information required by or under authority of the act to appear on the label shall appear thereon in the foreign language.” The labeling for Alcohol Isopropilico Hand Sanitizer Limar is misbranded under section 502(c) of the FD&C Act, 21 U.S.C. 352(c), because it is not labeled in accordance to 21 CFR 201.15. For example, the label does not include a “Drug Facts” panel in the Spanish language.\n\nAlcohol Isopropilico Hand Sanitizer Limar is in a 4 fluid ounce container that resembles a drinking water bottle customarily purchased by U.S. consumers. Section 502(i)(1) of the FD&C Act, 21 U.S.C. 352(i)(1), provides that a drug is misbranded if “its container is so made, formed, or filled as to be misleading . . .” As such, your clear, colorless hand sanitizer that fills a 4 fluid ounce container resembling plastic bottles ordinarily used to package drinking water is misbranded under section 502(i)(1) of the FD&C Act, 21 U.S.C. 352(i)(1).\n\nAlcohol Isopropilico Hand Sanitizer Limar is misbranded under section 502(x) of the FD&C Act, 21 U.S.C. 352(x), because the product label fails to disclose a domestic address or domestic telephone number through which the responsible person may receive a report of a serious adverse event with such drug.\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because Alcohol Isopropilico Hand Sanitizer Limar is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on June 30, 2021, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nPlease identify your response with FEI 3012644697 and ATTN: Tamara Rosbury.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\ncc:\n\nRegistered U.S. Agent\n\nRegistrar Corp\n\n144 Research Drive\n\nHampton, VA 23666\n\nUSA\n\n________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution of hand sanitizer products manufactured at your facility, a review of the purported formulations on the drug products’ labeling further indicates that such products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution. 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n3 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because Alcohol Isopropilico Hand Sanitizer Limar is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.","Ardil Comercial S.R.L.","ardil-comercial-srl-612018-09222021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fardil-comercial-srl-612018-09222021","2026-10-26T08:07:57.262866+00:00","Warning Letter","Issued","2021-10-05","612018","Drugs","Ms. Cecilia Ramirez","2026-08-20T02:34:37.561+00:00","VIA UPS","2021-09-22",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},734,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2025-08-05T04:00:00Z\">08\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-06-27T04:00:00Z\">06\u002F27\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmectronic-medicale-srl-707997-06272025\">Mectronic Medicale S.R.L. \u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ennio Aloisini\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Mectronic Medicale S.R.L. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Via Orio Al Serio 15\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>24050\u003C\u002Fspan> \u003Cspan>BG\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Italy\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)@mecmedix.com\"> (b)(4)@mecmedix.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 707997\u003C\u002Fp>\u003Cp>June 27, 2025\u003Cbr>\u003Cbr>Dear Mr. Aloisini:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Bergamo, Italy from February 24, 2025, through February 27, 2025, an investigator from the United States Food and Drug Administration (FDA, we, or the agency) determined that your firm manufactures CHELT, Ixyon XP, iLux Smart, iLux Plus, Doctor Tecar, Doctor Tecar Smart, and Doctor Tecar Plus devices. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. In addition, under section 531(2) of the Act, 21 U.S.C. § 360hh(2), each of these products is an electronic product because it is (A) a manufactured or assembled product which, when in operation, (i) contains or acts as part of an electronic circuit and (ii) emits (or in the absence of effective shielding or other controls would emit) electronic product radiation, or (B) a manufactured or assembled article which is intended for use as a component, part, or accessory of a product described in clause (A) and which when in operation emits (or in the absence of effective shielding or other controls would emit) such radiation.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain a DHF for each type of device, as required by 21 CFR 820.30(j).\u003C\u002Fp>\u003Cp>For example: Your firm’s design control procedures, PO_7.3_Design and Development, state the design elements requirements of the quality system regulation (i.e., Design and Development Planning, Design Input, Design Output, Design Verification, Design Validation, Design Transfer, and Design Changes) and that these design elements should be documented. However, a review of your firm’s therapeutic RF, laser, and laser\u002Fcryotherapy family Design History Files (DHF) demonstrated that your firm did not adequately document any of these design elements required per 21 CFR 820.30 Design Controls. For example, the three reviewed DHFs documented short statements or phrases of what occurred during each phase, but your firm failed to document any objective evidence of the activities conducted during all design phases for the three product families.\u003C\u002Fp>\u003Cp>2. Failure to ensure that where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fp>\u003Cp>For example: Your firm has stated that it has not established process validation where the results of a process cannot be fully verified by subsequent inspection and test. For example, your firm has not validated your output calibration system based on an established procedure. Your firm stated that you have not established process validation and\u002For test method validation procedures for your output calibration system, consisting of an \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used in the production of your therapeutic RF emitting device. Additionally, your firm did not have any records of performing validation of the system\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90.\u003C\u002Fp>\u003Cp>For example: Your firm did not properly identify and segregate nonconforming products. Your firm’s procedure, PO_8.3_Nonconformity Management, states that defective parts should be identified by means of red sticker, NCM identification code, and product is to be segregated in the area designated for nonconformities. However, during the inspection component was found outside of designated quarantine areas and nonconforming product was found lacking a red sticker and identification code.\u003C\u002Fp>\u003Cp>Additionally, a production record for a Doctor Tecar RF therapeutic device, serial number DT07222, was reviewed during the inspection. The record indicated that the product was nonconforming as it failed to meet the peak-to-peak voltage (Vpp) output specification for one of the frequency\u002Fpower combinations during device acceptance. However, your firm failed to identify this device as nonconforming and the product was released without justification or assessment.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures acceptance activities, as required by 21 CFR 820.80.\u003C\u002Fp>\u003Cp>For example: During the inspection your firm was unable to provide procedures for receiving inspection and stated that receiving inspection procedures have not been established. For example, your firm stated that they performed a 100% verification of laser diode power output and identified these as critical components used in your firm’s therapeutic devices. However, the laser diode acceptance activities were recorded on an uncontrolled document without identifying the test equipment used (e.g., laser power meter), nor its operator performing the test. These were not recorded in your firm’s Device History Record.\u003C\u002Fp>\u003Cp>5. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>For example: During the inspection, your firm’s management stated that they could not provide any specific complaint records because none had been documented to date. Your firm’s procedure, PO_8.2.1_Return Information section 8.2, requires complaints to be documented on the form, MOD_8.3a_NC and AC\u002FAP. The form is also used in the assessment of the complaints to determine the need to open and manage a corrective action. Your firm provided a complaint log which listed 22 complaints that your firm received. However, your firm was not able to provide evidence that these complaints were reviewed and evaluated by a formally designated unit.\u003C\u002Fp>\u003Cp>6. Failure to establish and maintain instructions and procedures for performing and verifying that the servicing meets the specified requirements, as required by 21 CFR 820.200.\u003C\u002Fp>\u003Cp>For example: Your firm’s servicing procedures, PO_7.5a_Production and delivery of services, section 6.7, generally describe your firm’s service products and generates a corresponding service record for all of your firm’s products. However, the procedures do not contain any specific information about how to perform routine servicing activities, acceptance testing following servicing, nor documentation requirements. Additionally, your firm provided a service record for a Doctor Tecar Plus device, serial# DTP07522, and it did not document the UDI of the service device. Furthermore, \u003Cstrong>(b)(4)\u003C\u002Fstrong> quantitative acceptance points were only recorded as two check marks on a separate uncontrolled document.\u003C\u002Fp>\u003Cp>7. Failure to establish procedures for identifying training needs and ensure that all personal are trained to adequately perform their assigned responsibilities, as required by 21 CFR 820.25(b).\u003C\u002Fp>\u003Cp>For example: Your firm’s procedure, PO_6.2_Training, requires management to define the training needs of employees on Form 6.2.3a Training Planning and for the identified internal training to be documented. However, your firm could not provide your training plan and training records for your production employees.\u003C\u002Fp>\u003Cp>8. Failure to maintain device history records as required by 21 CFR 820.184.\u003C\u002Fp>\u003Cp>For example: Your firm failed to document a copy of the primary product labeling for the Doctor Tecar device in each instance based on the inspection for 10 DHRs. This includes the handpiece label with a corresponding serial number and unit\u002Fconsole label with a corresponding serial number and UDI.\u003C\u002Fp>\u003Cp>9. Failure to establish procedures for quality audits and conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22.\u003C\u002Fp>\u003Cp>For example: Your firm’s procedures, for internal audits, P O _8.2.4_Inspection Visits, require that internal auditors to not have direct responsibility in the areas they audit to ensure that the auditors are independent. However, your firm’s Administrative, Financial, &amp; Quality Manager audited the quality system areas that they have direct responsibility over. For example, the Administrative, Financial &amp; Quality Manager audited:\u003C\u002Fp>\u003Cul>\u003Cli>CY2025 Internal audit plan – Coverage of monitoring of products and processes (i.e. final device acceptance), CAPA and Non-conformances.\u003C\u002Fli>\u003Cli>CY2024 Internal audit plan and completed internal audit record – Coverage of monitoring of products and processes (i.e. final device acceptance), CAPA and Non-conformances.\u003C\u002Fli>\u003Cli>CY2023 Internal audit plan and completed internal audit record – Coverage of your firm’s entire quality management system.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that your firm has failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. Specifically, your firm has stated that it has not established any procedures for MDRs. These would include establishing procedures for timely and effective identification, communication, and evaluation of reportable events, a standardized review process for determining when an event meets reportability criteria, timely submission of MDRs to the FDA, and compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\u003Cp>A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\u003C\u002Fp>\u003Cp>In response to this letter, please provide any completed actions taken by your firm to address this item or your planned actions and the timeframe for when these actions will be completed.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that the devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, intended for a use different from the intended use of a legally marketed device, without submitting a premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>1. Your Doctor Tecar, Doctor Tecar Smart, and Doctor Tecar Plus devices have been cleared for the following indications:\u003C\u002Fp>\u003Cp>K221043 – Doctor Tecar Plus and Doctor Tecar Smart devices are intended to provide topical heating for the purpose of elevating tissue temperature for treatment of selected medical conditions such as: relief of pain, muscle spasms, increase in local circulation.\u003C\u002Fp>\u003Cp>K183693 – The Doctor Tecar device is intended to provide topical heating for the purpose of elevating tissue temperature for treatment of selected medical conditions such as relief of pain, muscle spasms, and increase in local circulation.\u003C\u002Fp>\u003Cp>However, you are marketing these devices without clearance for the following uses in your marketing materials, including but not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>“Doctor Tecar Therapy is an innovative, high-performance therapy in the treatment of Carpal Tunnel Syndrome.”\u003C\u002Fli>\u003Cli>“Doctor Tecar Therapy not only provides rapid pain relief, but also accelerates the healing process, significantly reducing recovery time and improving the effectiveness of treatments.”\u003C\u002Fli>\u003Cli>“Accelerated Healing: Boosts cellular metabolism for faster and more effective rehabilitation.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>These statements were not reviewed as part of your premarket notification materials submitted to FDA and are outside of the scope of the clearances issued under K221043 and K183693. FDA is currently unaware of any evidence that could support the above intended uses. These statements appear to constitute changes in the intended use of the products that require submission of a new 510(k), as provided by 21 CFR 807.81(a)(3)(ii). These new intended uses raise effectiveness concerns that are different from those normally associated with the cleared uses of the device. These topical heating devices use energy to generate heat within layers of the skin and require performance testing for specific indications for use that presume a specific clinical outcome. The above-mentioned new treatment claims have not been evaluated in the 510(k) submissions and substantiated by supporting data for the new treatment claims such as any clinical data demonstrating the treatment of Carpal Tunnel Syndrome, reduced recovery time and boosting of cellular metabolism. Patients who use this device may forego other known therapies and delay addressing their health concerns that may result in serious injury or lengthen recovery times.\u003C\u002Fp>\u003Cp>2. The FDA has reviewed the user manuals for the CHELT, iLux Plus, iLux Smart, and Ixyon XP devices, which your firm introduced or delivered for introduction these devices into interstate commerce for commercial distribution, and which you have listed in FDA’s registration and listing database as intended for use in the generic type of device described at 21 CFR 890.5500 (infrared lamp) and product code ILY (lamp, infrared, therapeutic heating). Devices regulated under 21 CFR 890.5500 and ILY are exempt from premarket notification unless they exceed the limitations of exemption described in 21 CFR 890.9(a). However, there is evidence that the CHELT, Ixyon XP, iLux Smart, and iLux Plus are intended for uses that are different from those of legally marketed devices regulated under 21 CFR 890.5500 and ILY.\u003C\u002Fp>\u003Cp>Generic devices of this type emit energy at infrared frequencies (approximately 700 to 50,000 nanometers) to provide topical heating and are intended for medical purposes including, but not limited to, temporary increase in local blood circulation and temporary relief of: muscle spasms, minor joint pain and stiffness, minor muscle pain and stiffness, and minor arthritis pain. However, your firm is marketing the CHELT, Ixyon XP, iLux Smart, and iLux Plus for different specific intended uses, namely “f\u003Cem>or the treatment of pathologies of the musculoskeletal system such as lumbago, cervicalgia, epicondylitis, medial epicondylitis, . . . as well as contractures . . .\u003C\u002Fem>” FDA is currently unaware of any clinical evidence that could support these intended uses. These uses increase the risk of injury because of deeper tissue penetration, and potentially higher energy and temperature delivery to target structures not addressed in legally marketed ILY devices. The specific conditions including lumbago, cervicalgia, epicondylitis, medial epicondylitis, and contractures, involve anatomical sites that are more sensitive than superficial muscle groups. Treating these conditions with infrared heating or high-intensity laser therapy can result in overheating of deeper tissues, burns, nerve injury, or damage to underlying structures. Additionally, these new indications introduce uncertainty about safety and efficacy because there is no validated clinical evidence to support the benefits outweighing the risks for these specific treatment indications. These risks are not present in currently cleared or exempted ILY indications, which are limited to superficial, non-specific pain relief through mild, topical heating. The devices are therefore not exempt from the 510(k) requirement as described in 21 CFR 807.81(a)(3)(ii).\u003C\u002Fp>\u003Cp>In addition, the CHELT, Ixyon XP, iLux Smart, and iLux Plus devices include a maximum threshold for a skin surface temperature of 50°C. A safe and effective therapeutic skin surface temperature range for infrared lamps is 40 - 45°C because skin surface temperatures greater than 45°C present a risk of skin burns in generic devices of this type. The 50°C maximum skin surface temperature threshold is a different technological characteristic for this generic device type. Because there is evidence that the CHELT, Ixyon XP, iLux Smart, and iLux Plus have different intended uses and technology compared with that of legally marketed devices classified under 21 CFR 890.5500, the devices exceed the limitations described in 21 CFR 890.9(b) and are not exempt from premarket notification requirements. They are also therefore subject to the requirement under 21 CFR 807.81(3)(a)(i).\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Electronic Product Radiation Control Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm failed to comply with reporting requirements applicable to electronic products under 21 CFR Chapter I, Subchapter J – Radiological Health. Section 538(a) of the Act (21 U.S.C. 360oo(a)) prohibits, in part, any person to fail or refuse to make any report, or furnish or preserve any information required by section 537 of the Act (21 U.S.C. 360nn).\u003C\u002Fp>\u003Cp>In addition to being a \"device,\" Ixyon therapeutic laser family of devices are \"electronic products\" subject to compliance with Chapter V, Subchapter C of the Act, Electronic Product Radiation Control (21 U.S.C. 360hh et seq.) and the general requirements at 21 CFR Parts 1000-1005, including reporting requirements at 21 CFR Part 1002, which are prescribed pursuant to section 537 of the Act.\u003C\u002Fp>\u003Cp>Significant violations include, but are not limited to, failure to submit a radiation safety product report followed by annual reports as required by 21 CFR 1002.10 and 1002.13, respectively. For example, during the inspection, Ms. Chiara (NMI) Borgonovo, Export Area Manager, clarified that Mectronic Medicale S.R.L. has shipped eight (8) laser devices to the US for sales purposes. A review of our records indicates that the required radiation safety report (21 CFR 1002.10) for your company’s Ixyon therapeutic laser family of devices has not been received by FDA. In addition, FDA has not received the required annual reports for the CHELT model of products (21 CFR 1002.13).\u003C\u002Fp>\u003Cp>Manufacturers of laser products are responsible for assuring their products comply with all applicable mandatory federal radiation safety performance standards prior to entry of those products into US commerce. For medical lasers, the applicable performance standards are 21 CFR Part 1010, 1040.10, and 1040.11(a). Additionally, manufacturers of these products are subject to all applicable requirements of Title 21 CFR Parts 1000 – 1005, which includes the reporting and record keeping requirements found in Title 21 CFR Part 1002.\u003C\u002Fp>\u003Cp>We also note that, while FDA has stated the agency does not intend to enforce the requirements of 21 CFR 1040.10 and 1040.11(a) if the laser products have incorporated the comparable clause of IEC 60825-1 Ed. 3 (see FDA’s Laser Notice 56 available here: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110120\u002Fdownload), the applicable “DANGER” phrase (see IEC 60825-1 Ed. 3, clause 7.7) is missing from the warning logotype label as depicted in the user manuals of the Ixyon, iLux, and CHELT therapeutic laser family of devices.\u003C\u002Fp>\u003Cp>Please revise your warning logotype labels for compliance with the applicable requirements outlined in 21 CFR 1040.10(g)(3), which FDA considers to be comparable to conformance with IEC 60825-1 Ed. 3, clause 7.7. Please submit the revised labels as part of your response to this correspondence.\u003C\u002Fp>\u003Cp>For therapeutic laser devices that do not currently have a radiation safety report on file, please ensure that copies of compliant warning logotype labels are included in all future submissions.\u003C\u002Fp>\u003Cp>Additionally, you should update your company’s quality control procedures to ensure that all future production units intended to enter the U.S. commerce bear the required warning logotype label. Copies of the labels must also be included in relevant promotional materials, such as the device user manual as required per 21 CFR 1040.10(h)(1)(iii).\u003C\u002Fp>\u003Cp>Please also provide the following information: (a) list all models of laser products your firm manufactured and imported to the US, and (b) whether Mectronic Medicale S.R.L. certified each laser product which entered commerce as required by Title 21 CFR 1010.2. Please note that medical laser product certification according to 21 CFR 1010.2 and ISO 13485 certification are not the same. The FDA regulation (21 CFR 1010.2) specifically addresses laser product safety and performance standards in the U.S., while ISO 13485 is an international standard for quality management systems in medical device manufacturing. The FDA certification focuses on the product itself, whereas ISO 13485 covers broader organizational processes and quality management. While both are relevant for medical laser manufacturers, they serve distinct purposes in regulatory compliance and quality assurance.\u003C\u002Fp>\u003Cp>Copies of the Federal Performance Standards, compliance guides, radiation safety product report guides, and other documents related to laser products are available on FDA’s web site at: http:\u002F\u002Fwww.fda.gov\u002FRadiation-EmittingProducts\u002Fdefault.htm, and https:\u002F\u002Fwww.fda.gov\u002Fradiation-emitting-products\u002Fsurgical-and-therapeutic-products\u002Fmedical-lasers.\u003C\u002Fp>\u003Cp>Please submit the missing radiation safety reports for all models that are already imported into the US, or that you plan to enter the US market. Please use Form FDA 3632 to prepare your radiation safety product reports, and form FDA 3636 for the annual report. All Radiation Safety reports and supporting materials can be submitted to the FDA by email at: RadHealthCustomerService@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to correct the above deficiencies. Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\u003C\u002Fp>\u003Cp>Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to James Jang at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 707997” when replying. If you have any questions about the contents of this letter, please contact: Andrew Keys at Andrew.Keys@FDA.HHS.Gov\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices and electronic products. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Bleta Vuniqi Houtkamp\u003Cbr>Deputy Office Director\u003Cbr>OHT4: Office of Surgical and Infection Control Devices\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Jerry Doane\u003Cbr>Pragmatic Compliance dba FDAbasics&nbsp;&nbsp;\u003Cbr>15815 SW 11th Court Rd\u003Cbr>Ocala, FL US 34473\u003Cbr>Usagent@fdabasics.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nEnnio Aloisini\n\nRecipient Title\n\nChief Executive Officer\n\nMectronic Medicale S.R.L.\n\nVia Orio Al Serio 15\n\n24050 BG\n\nItaly\n\n(b)(4)@mecmedix.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 707997\nJune 27, 2025\n\nDear Mr. Aloisini:\nDuring an inspection of your firm located in Bergamo, Italy from February 24, 2025, through February 27, 2025, an investigator from the United States Food and Drug Administration (FDA, we, or the agency) determined that your firm manufactures CHELT, Ixyon XP, iLux Smart, iLux Plus, Doctor Tecar, Doctor Tecar Smart, and Doctor Tecar Plus devices. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. In addition, under section 531(2) of the Act, 21 U.S.C. § 360hh(2), each of these products is an electronic product because it is (A) a manufactured or assembled product which, when in operation, (i) contains or acts as part of an electronic circuit and (ii) emits (or in the absence of effective shielding or other controls would emit) electronic product radiation, or (B) a manufactured or assembled article which is intended for use as a component, part, or accessory of a product described in clause (A) and which when in operation emits (or in the absence of effective shielding or other controls would emit) such radiation.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain a DHF for each type of device, as required by 21 CFR 820.30(j).\nFor example: Your firm’s design control procedures, PO_7.3_Design and Development, state the design elements requirements of the quality system regulation (i.e., Design and Development Planning, Design Input, Design Output, Design Verification, Design Validation, Design Transfer, and Design Changes) and that these design elements should be documented. However, a review of your firm’s therapeutic RF, laser, and laser\u002Fcryotherapy family Design History Files (DHF) demonstrated that your firm did not adequately document any of these design elements required per 21 CFR 820.30 Design Controls. For example, the three reviewed DHFs documented short statements or phrases of what occurred during each phase, but your firm failed to document any objective evidence of the activities conducted during all design phases for the three product families.\n2. Failure to ensure that where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\nFor example: Your firm has stated that it has not established process validation where the results of a process cannot be fully verified by subsequent inspection and test. For example, your firm has not validated your output calibration system based on an established procedure. Your firm stated that you have not established process validation and\u002For test method validation procedures for your output calibration system, consisting of an (b)(4) and (b)(4), used in the production of your therapeutic RF emitting device. Additionally, your firm did not have any records of performing validation of the system\n3. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90.\nFor example: Your firm did not properly identify and segregate nonconforming products. Your firm’s procedure, PO_8.3_Nonconformity Management, states that defective parts should be identified by means of red sticker, NCM identification code, and product is to be segregated in the area designated for nonconformities. However, during the inspection component was found outside of designated quarantine areas and nonconforming product was found lacking a red sticker and identification code.\nAdditionally, a production record for a Doctor Tecar RF therapeutic device, serial number DT07222, was reviewed during the inspection. The record indicated that the product was nonconforming as it failed to meet the peak-to-peak voltage (Vpp) output specification for one of the frequency\u002Fpower combinations during device acceptance. However, your firm failed to identify this device as nonconforming and the product was released without justification or assessment.\n4. Failure to establish and maintain procedures acceptance activities, as required by 21 CFR 820.80.\nFor example: During the inspection your firm was unable to provide procedures for receiving inspection and stated that receiving inspection procedures have not been established. For example, your firm stated that they performed a 100% verification of laser diode power output and identified these as critical components used in your firm’s therapeutic devices. However, the laser diode acceptance activities were recorded on an uncontrolled document without identifying the test equipment used (e.g., laser power meter), nor its operator performing the test. These were not recorded in your firm’s Device History Record.\n5. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nFor example: During the inspection, your firm’s management stated that they could not provide any specific complaint records because none had been documented to date. Your firm’s procedure, PO_8.2.1_Return Information section 8.2, requires complaints to be documented on the form, MOD_8.3a_NC and AC\u002FAP. The form is also used in the assessment of the complaints to determine the need to open and manage a corrective action. Your firm provided a complaint log which listed 22 complaints that your firm received. However, your firm was not able to provide evidence that these complaints were reviewed and evaluated by a formally designated unit.\n6. Failure to establish and maintain instructions and procedures for performing and verifying that the servicing meets the specified requirements, as required by 21 CFR 820.200.\nFor example: Your firm’s servicing procedures, PO_7.5a_Production and delivery of services, section 6.7, generally describe your firm’s service products and generates a corresponding service record for all of your firm’s products. However, the procedures do not contain any specific information about how to perform routine servicing activities, acceptance testing following servicing, nor documentation requirements. Additionally, your firm provided a service record for a Doctor Tecar Plus device, serial# DTP07522, and it did not document the UDI of the service device. Furthermore, (b)(4) quantitative acceptance points were only recorded as two check marks on a separate uncontrolled document.\n7. Failure to establish procedures for identifying training needs and ensure that all personal are trained to adequately perform their assigned responsibilities, as required by 21 CFR 820.25(b).\nFor example: Your firm’s procedure, PO_6.2_Training, requires management to define the training needs of employees on Form 6.2.3a Training Planning and for the identified internal training to be documented. However, your firm could not provide your training plan and training records for your production employees.\n8. Failure to maintain device history records as required by 21 CFR 820.184.\nFor example: Your firm failed to document a copy of the primary product labeling for the Doctor Tecar device in each instance based on the inspection for 10 DHRs. This includes the handpiece label with a corresponding serial number and unit\u002Fconsole label with a corresponding serial number and UDI.\n9. Failure to establish procedures for quality audits and conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22.\nFor example: Your firm’s procedures, for internal audits, P O _8.2.4_Inspection Visits, require that internal auditors to not have direct responsibility in the areas they audit to ensure that the auditors are independent. However, your firm’s Administrative, Financial, & Quality Manager audited the quality system areas that they have direct responsibility over. For example, the Administrative, Financial & Quality Manager audited:\nCY2025 Internal audit plan – Coverage of monitoring of products and processes (i.e. final device acceptance), CAPA and Non-conformances.\nCY2024 Internal audit plan and completed internal audit record – Coverage of monitoring of products and processes (i.e. final device acceptance), CAPA and Non-conformances.\nCY2023 Internal audit plan and completed internal audit record – Coverage of your firm’s entire quality management system.\nMedical Device Reporting (MDR) Violation(s)\nOur inspection revealed that your firm has failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. Specifically, your firm has stated that it has not established any procedures for MDRs. These would include establishing procedures for timely and effective identification, communication, and evaluation of reportable events, a standardized review process for determining when an event meets reportability criteria, timely submission of MDRs to the FDA, and compliance with the applicable documentation and recordkeeping requirements.\nA device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\nIn response to this letter, please provide any completed actions taken by your firm to address this item or your planned actions and the timeframe for when these actions will be completed.\nUnapproved Device Violation(s)\nOur inspection also revealed that the devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, intended for a use different from the intended use of a legally marketed device, without submitting a premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n1. Your Doctor Tecar, Doctor Tecar Smart, and Doctor Tecar Plus devices have been cleared for the following indications:\nK221043 – Doctor Tecar Plus and Doctor Tecar Smart devices are intended to provide topical heating for the purpose of elevating tissue temperature for treatment of selected medical conditions such as: relief of pain, muscle spasms, increase in local circulation.\nK183693 – The Doctor Tecar device is intended to provide topical heating for the purpose of elevating tissue temperature for treatment of selected medical conditions such as relief of pain, muscle spasms, and increase in local circulation.\nHowever, you are marketing these devices without clearance for the following uses in your marketing materials, including but not limited to:\n“Doctor Tecar Therapy is an innovative, high-performance therapy in the treatment of Carpal Tunnel Syndrome.”\n“Doctor Tecar Therapy not only provides rapid pain relief, but also accelerates the healing process, significantly reducing recovery time and improving the effectiveness of treatments.”\n“Accelerated Healing: Boosts cellular metabolism for faster and more effective rehabilitation.”\nThese statements were not reviewed as part of your premarket notification materials submitted to FDA and are outside of the scope of the clearances issued under K221043 and K183693. FDA is currently unaware of any evidence that could support the above intended uses. These statements appear to constitute changes in the intended use of the products that require submission of a new 510(k), as provided by 21 CFR 807.81(a)(3)(ii). These new intended uses raise effectiveness concerns that are different from those normally associated with the cleared uses of the device. These topical heating devices use energy to generate heat within layers of the skin and require performance testing for specific indications for use that presume a specific clinical outcome. The above-mentioned new treatment claims have not been evaluated in the 510(k) submissions and substantiated by supporting data for the new treatment claims such as any clinical data demonstrating the treatment of Carpal Tunnel Syndrome, reduced recovery time and boosting of cellular metabolism. Patients who use this device may forego other known therapies and delay addressing their health concerns that may result in serious injury or lengthen recovery times.\n2. The FDA has reviewed the user manuals for the CHELT, iLux Plus, iLux Smart, and Ixyon XP devices, which your firm introduced or delivered for introduction these devices into interstate commerce for commercial distribution, and which you have listed in FDA’s registration and listing database as intended for use in the generic type of device described at 21 CFR 890.5500 (infrared lamp) and product code ILY (lamp, infrared, therapeutic heating). Devices regulated under 21 CFR 890.5500 and ILY are exempt from premarket notification unless they exceed the limitations of exemption described in 21 CFR 890.9(a). However, there is evidence that the CHELT, Ixyon XP, iLux Smart, and iLux Plus are intended for uses that are different from those of legally marketed devices regulated under 21 CFR 890.5500 and ILY.\nGeneric devices of this type emit energy at infrared frequencies (approximately 700 to 50,000 nanometers) to provide topical heating and are intended for medical purposes including, but not limited to, temporary increase in local blood circulation and temporary relief of: muscle spasms, minor joint pain and stiffness, minor muscle pain and stiffness, and minor arthritis pain. However, your firm is marketing the CHELT, Ixyon XP, iLux Smart, and iLux Plus for different specific intended uses, namely “for the treatment of pathologies of the musculoskeletal system such as lumbago, cervicalgia, epicondylitis, medial epicondylitis, . . . as well as contractures . . .” FDA is currently unaware of any clinical evidence that could support these intended uses. These uses increase the risk of injury because of deeper tissue penetration, and potentially higher energy and temperature delivery to target structures not addressed in legally marketed ILY devices. The specific conditions including lumbago, cervicalgia, epicondylitis, medial epicondylitis, and contractures, involve anatomical sites that are more sensitive than superficial muscle groups. Treating these conditions with infrared heating or high-intensity laser therapy can result in overheating of deeper tissues, burns, nerve injury, or damage to underlying structures. Additionally, these new indications introduce uncertainty about safety and efficacy because there is no validated clinical evidence to support the benefits outweighing the risks for these specific treatment indications. These risks are not present in currently cleared or exempted ILY indications, which are limited to superficial, non-specific pain relief through mild, topical heating. The devices are therefore not exempt from the 510(k) requirement as described in 21 CFR 807.81(a)(3)(ii).\nIn addition, the CHELT, Ixyon XP, iLux Smart, and iLux Plus devices include a maximum threshold for a skin surface temperature of 50°C. A safe and effective therapeutic skin surface temperature range for infrared lamps is 40 - 45°C because skin surface temperatures greater than 45°C present a risk of skin burns in generic devices of this type. The 50°C maximum skin surface temperature threshold is a different technological characteristic for this generic device type. Because there is evidence that the CHELT, Ixyon XP, iLux Smart, and iLux Plus have different intended uses and technology compared with that of legally marketed devices classified under 21 CFR 890.5500, the devices exceed the limitations described in 21 CFR 890.9(b) and are not exempt from premarket notification requirements. They are also therefore subject to the requirement under 21 CFR 807.81(3)(a)(i).\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nElectronic Product Radiation Control Device Violation(s)\nOur inspection also revealed that your firm failed to comply with reporting requirements applicable to electronic products under 21 CFR Chapter I, Subchapter J – Radiological Health. Section 538(a) of the Act (21 U.S.C. 360oo(a)) prohibits, in part, any person to fail or refuse to make any report, or furnish or preserve any information required by section 537 of the Act (21 U.S.C. 360nn).\nIn addition to being a \"device,\" Ixyon therapeutic laser family of devices are \"electronic products\" subject to compliance with Chapter V, Subchapter C of the Act, Electronic Product Radiation Control (21 U.S.C. 360hh et seq.) and the general requirements at 21 CFR Parts 1000-1005, including reporting requirements at 21 CFR Part 1002, which are prescribed pursuant to section 537 of the Act.\nSignificant violations include, but are not limited to, failure to submit a radiation safety product report followed by annual reports as required by 21 CFR 1002.10 and 1002.13, respectively. For example, during the inspection, Ms. Chiara (NMI) Borgonovo, Export Area Manager, clarified that Mectronic Medicale S.R.L. has shipped eight (8) laser devices to the US for sales purposes. A review of our records indicates that the required radiation safety report (21 CFR 1002.10) for your company’s Ixyon therapeutic laser family of devices has not been received by FDA. In addition, FDA has not received the required annual reports for the CHELT model of products (21 CFR 1002.13).\nManufacturers of laser products are responsible for assuring their products comply with all applicable mandatory federal radiation safety performance standards prior to entry of those products into US commerce. For medical lasers, the applicable performance standards are 21 CFR Part 1010, 1040.10, and 1040.11(a). Additionally, manufacturers of these products are subject to all applicable requirements of Title 21 CFR Parts 1000 – 1005, which includes the reporting and record keeping requirements found in Title 21 CFR Part 1002.\nWe also note that, while FDA has stated the agency does not intend to enforce the requirements of 21 CFR 1040.10 and 1040.11(a) if the laser products have incorporated the comparable clause of IEC 60825-1 Ed. 3 (see FDA’s Laser Notice 56 available here: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110120\u002Fdownload), the applicable “DANGER” phrase (see IEC 60825-1 Ed. 3, clause 7.7) is missing from the warning logotype label as depicted in the user manuals of the Ixyon, iLux, and CHELT therapeutic laser family of devices.\nPlease revise your warning logotype labels for compliance with the applicable requirements outlined in 21 CFR 1040.10(g)(3), which FDA considers to be comparable to conformance with IEC 60825-1 Ed. 3, clause 7.7. Please submit the revised labels as part of your response to this correspondence.\nFor therapeutic laser devices that do not currently have a radiation safety report on file, please ensure that copies of compliant warning logotype labels are included in all future submissions.\nAdditionally, you should update your company’s quality control procedures to ensure that all future production units intended to enter the U.S. commerce bear the required warning logotype label. Copies of the labels must also be included in relevant promotional materials, such as the device user manual as required per 21 CFR 1040.10(h)(1)(iii).\nPlease also provide the following information: (a) list all models of laser products your firm manufactured and imported to the US, and (b) whether Mectronic Medicale S.R.L. certified each laser product which entered commerce as required by Title 21 CFR 1010.2. Please note that medical laser product certification according to 21 CFR 1010.2 and ISO 13485 certification are not the same. The FDA regulation (21 CFR 1010.2) specifically addresses laser product safety and performance standards in the U.S., while ISO 13485 is an international standard for quality management systems in medical device manufacturing. The FDA certification focuses on the product itself, whereas ISO 13485 covers broader organizational processes and quality management. While both are relevant for medical laser manufacturers, they serve distinct purposes in regulatory compliance and quality assurance.\nCopies of the Federal Performance Standards, compliance guides, radiation safety product report guides, and other documents related to laser products are available on FDA’s web site at: http:\u002F\u002Fwww.fda.gov\u002FRadiation-EmittingProducts\u002Fdefault.htm, and https:\u002F\u002Fwww.fda.gov\u002Fradiation-emitting-products\u002Fsurgical-and-therapeutic-products\u002Fmedical-lasers.\nPlease submit the missing radiation safety reports for all models that are already imported into the US, or that you plan to enter the US market. Please use Form FDA 3632 to prepare your radiation safety product reports, and form FDA 3636 for the annual report. All Radiation Safety reports and supporting materials can be submitted to the FDA by email at: RadHealthCustomerService@fda.hhs.gov.\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nThis letter notifies you of our findings and provides you an opportunity to correct the above deficiencies. Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\nPlease provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to James Jang at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 707997” when replying. If you have any questions about the contents of this letter, please contact: Andrew Keys at Andrew.Keys@FDA.HHS.Gov\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices and electronic products. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBleta Vuniqi Houtkamp\nDeputy Office Director\nOHT4: Office of Surgical and Infection Control Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nJerry Doane\nPragmatic Compliance dba FDAbasics\n15815 SW 11th Court Rd\nOcala, FL US 34473\nUsagent@fdabasics.com","Mectronic Medicale S.R.L.","mectronic-medicale-srl-707997-06272025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmectronic-medicale-srl-707997-06272025","2026-10-26T08:09:22.482246+00:00","2025-08-05","707997","Medical Devices","Ennio Aloisini","2026-08-19T16:31:34.745+00:00","2025-06-27",{"id":53,"raw":54,"subject":38,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":66,"posted_date":67,"marcs_cms_no":68,"product_type":48,"closeout_date":69,"issuing_office":37,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},2214,[55,56,57,37,38,13,58,13],"\u003Ctime datetime=\"2023-02-07T14:20:00Z\">02\u002F07\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-30T04:00:00Z\">09\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrovention-costa-rica-srl-643188-09302022\">MicroVention Costa Rica S.R.L.\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrovention-costa-rica-srl-643188-09162025\">\u003Ctime datetime=\"2025-11-17T05:00:00Z\">11\u002F17\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Charlie Noel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>SVP, International Operations-CR\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MicroVention Costa Rica S.R.L.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Coyol Free Zone, B 33 Zona Franca Coyol, Edificio B33\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>El Coyol De Alajuela\u003C\u002Fspan>, \u003Cspan>Alajuela\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>20101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Costa Rica\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 30, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Charlie Noel:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Alajuela, Costa Rica, on May 23, 2022, through May 26, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Headway Microcatheter, LVIS, LVIS Jr, Scepter C and XC Occlusion Balloon Catheter, SOFIA Catheters, and BOBBY Balloon Guide Catheter. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received responses from Scafford Serron, Ph.D., VP of Global Quality dated June 16, 2022, July 18, 2022, and August 18, 2022, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1.&nbsp;Failure to verify a process that cannot be fully verified by subsequent inspection and test with a high degree of assurance and approved according to established procedures. The validation activities and results, including the date and signature of the individual(s) approving the validation and where appropriate the major equipment validated, shall be documented, as required by 21 CFR 820.75(a) – Process Validation. For example:\u003C\u002Fp>\n\n\u003Cp>a. The catheter wash limitation process justifications \u003Cstrong>(b)(4)\u003C\u002Fstrong> dated October 31,2018 and \u003Cstrong>(b)(4)\u003C\u002Fstrong> dated June 10, 2021, do not specify the requirements for the catheter wash process validation prior to conducting the process validation. Additionally, the justifications provided for several test parameters do not provide a high degree of assurance and were not approved according to established procedures. Prior to the 2018 validation, this process had not been validated according to established procedures. Therefore, it is unknown if the catheter wash process sufficiently removes foreign material from the manufacturing process.\u003C\u002Fp>\n\n\u003Cp>The responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm initiated CAPA\u003Cstrong>(b)(4)\u003C\u002Fstrong> to address Observation 1 and identified four root causes and training corrective actions, and conducted a retrospective review of processes requiring validation. Documents gathered at the inspection, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and provided in the response, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>(b)(4)\u003C\u002Fstrong> require biocompatibility testing comply with ISO 10993-1. However, CAPA\u003Cstrong>(b)(4)\u003C\u002Fstrong> does not provide a high degree of assurance, as addressed in the FDA-recognized standard ISO-10993 [Biocompatibility]. For example:\u003C\u002Fp>\n\n\u003Cp>i)&nbsp; Per Part 1 of ISO-10993, a gap analysis and selection of biological endpoints for assessment is necessary to assess the biological safety of the medical device. The proposed responses and corrective actions do not address all biological endpoints, including pyrogenicity.\u003C\u002Fp>\n\n\u003Cp>ii)&nbsp; Per Part 5 of ISO-10993, cytotoxicity testing standards require that the cytotoxicity be addressed at 24 hours and 48 hours, and that the results after 48 hours be less than or equal to Grade 2 by quantitative methods. The proposed responses and corrective actions incorrectly state the acceptance criteria to be, “Non cytotoxicity response with a test score of ≤2 at 24-Hour observation.”\u003C\u002Fp>\n\n\u003Cp>iii)&nbsp; The validation process and corrective actions fail to address the residual sterilant levels after the changed catheter wash procedure and device sterilization. Per ISO 10993-7, “A valid method of extraction and measurement shall be used to determine the amount of EO and, where necessary, ECH delivered to the patient.”\u003C\u002Fp>\n\n\u003Cp>iv)&nbsp; The proposed corrective actions do not address design transfer for the software validation functionality testing, in which there is failure to ensure that the device design is correctly translated into production specifications, as required by 21 CFR 820.30(h).\u003C\u002Fp>\n\n\u003Cp>b. It cannot be verified from the non-equipment software test report: coating tracker software \u003Cstrong>(b)(4)\u003C\u002Fstrong> that the tasks requiring a specific number of repeats for validation were conducted for the required number of repeats per the protocol.\u003C\u002Fp>\n\n\u003Cp>The responses dated June 16, 2022, July 18, 2022, and August 18, 2022 indicate that the root cause investigation is completed, additional review of all other previously completed non-equipment software production pertaining to the hydrophilic coating process were identified and are being implemented, and corrective actions are ongoing under CAPA\u003Cstrong>(b)(4)\u003C\u002Fstrong>. The adequacy of the responses cannot be determined until the outstanding inadequacies with CAPA\u003Cstrong>(b)(4)\u003C\u002Fstrong> under Observation 01 are addressed.\u003C\u002Fp>\n\n\u003Cp>2.&nbsp; Failure to establish and maintain adequate procedures for implementing and maintaining corrective and preventive actions, as required by 21 CFR 820.100. For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm’s Supplier Corrective Action Request (SCAR) Process \u003Cstrong>(b)(4)\u003C\u002Fstrong> requires that the firm open a SCAR “when it is determined that a supplier corrective action is need for an NCR” (Nonconformance Report). The FDA investigator collected examples of nonconformance reported quality problems where no SCAR was opened by your firm as required by its procedure. Additionally, because these corrective actions were taken as a result of these nonconformances outside of your firm’s corrective action procedures, no evaluation as to whether actions taken adversely affected the finished device was completed, nor were the corrections verified as effective, as required by 21 CFR 820.100(a)(4).\u003C\u002Fp>\n\n\u003Cp>The responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm initiated CAPA\u003Cstrong>(b)(4)\u003C\u002Fstrong> to address Observation 5 and identified five root causes. Your firm updated its procedure, \u003Cstrong>(b)(4)\u003C\u002Fstrong> to provide clarification to its employees as to when a SCAR needs to be initiated. Your firm submitted documentation that supports training of its employees on the new procedure. Your firm states that it will ensure each corrective and preventive action is effective through the Verification of Effectiveness process, though it is not clear exactly how and when that will occur. Your firm initiated a 3-year retrospective review of supplier NCR events where SCARs were not initiated and plans to evaluate any adverse effects of these NCRs as part of the CAPA underway. This activity is scheduled to be completed at the end of October 2022. The adequacy of your firm’s responses will be evaluated after you submit clarification of your plan to ensure effectiveness of the implemented corrective actions and documentation to support that effectiveness when complete.\u003C\u002Fp>\n\n\u003Cp>b. Your firm’s CAPA system fails to identify “rejects” as nonconforming product and therefore misses all nonconforming product during the manufacturing process as a quality data input for the CAPA system, as required by 21 CFR820.100(a)(1). Without nonconforming product as a quality data input to the CAPA system, the ability to detect recurring quality problems is greatly diminished.\u003C\u002Fp>\n\n\u003Cp>The responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm stated that its Quality Reporting procedure does require your firm to periodically review rejected material and that its employees “could” request a CAPA if they decided to based on that review. Your firm updated its CAPA procedure \u003Cstrong>(b)(4)\u003C\u002Fstrong> to include Reject data\u002Ftrend for consistent wording between its other relevant SOPs for Quality Reporting to be more clear that rejected material needs to be investigated as nonconforming product and that data needs to be fed into the CAPA system. Your firm stated that it has “made employees aware” and that effectiveness checks are planned to be completed by February 2023. It is not clear whether your firm has evaluated whether the periodic reviews of the rejected material historically have warranted an investigation. Information is needed to clarify whether a retrospective review has been completed or is planned.\u003C\u002Fp>\n\n\u003Cp>3.&nbsp; Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR 820.90(a). For example:\u003C\u002Fp>\n\n\u003Cp>During production and quality inspection, nonconforming product is identified as a “reject”. While rejected\u002Fnonconforming product is identified, documented, and segregated, the firm is not evaluating the nonconformance to determine the need for an investigation and notification of persons or organizations responsible for the nonconformance, as required by 21 CFR 820.90(a).\u003C\u002Fp>\n\n\u003Cp>The responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm made initial corrections to several procedures and definitions to ensure that rejected nonconforming product during the manufacturing process is accurately captured, trended, and fed into its CAPA system. Part of the issue related to a high reject rate was due to material that was destroyed during testing being labeled as “reject” in addition to actual nonconforming product. Your firm implemented an IT solution to label those samples separately as “destroyed” instead of “reject”. Your firm states that it has notified its relevant employees of the definition and procedure change. Your firm states that it plans to conduct effectiveness checks for CAPA \u003Cstrong>(b)(4)\u003C\u002Fstrong> and included the planned evaluation and timeframe for doing so, with a completion date of February 2023. Your firm also mentions a “preventive” action that plans to look at other product lines and systems where “reject” is used as a product designation to ensure that they are not missing any other nonconforming product documentation. It is not clear whether this includes a retrospective review of previous rejected materials in an attempt to determine whether an investigation needs to be opened into those nonconforming product. The adequacy of your firm’s responses will be evaluated after you provide information clarifying whether a retrospective review of rejected product will occur to determine whether an investigation can or should be done at this time.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration - CDRH\u002FORP\u002FDRP2\u003Cbr>\nCDRH Regulatory Inspections and Audit Team, WO66-1434\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Refer to CMS case # 472344 when replying\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact: Lydia Glaw, PhD at lydia.glaw@fda.hhs.gov or 301-796-1456.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Bram Zuckerman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Cardiovascular Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nAmy Smith\u003Cbr>\n35 Enterprise, Aliso Viejo, CA US 92656\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nCharlie Noel\n\nRecipient Title\n\nSVP, International Operations-CR\n\nMicroVention Costa Rica S.R.L.\n\nCoyol Free Zone, B 33 Zona Franca Coyol, Edificio B33\n\nEl Coyol De Alajuela, Alajuela\n\n20101\n\nCosta Rica\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nSeptember 30, 2022\n\nDear Charlie Noel:\n\nDuring an inspection of your firm located in Alajuela, Costa Rica, on May 23, 2022, through May 26, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Headway Microcatheter, LVIS, LVIS Jr, Scepter C and XC Occlusion Balloon Catheter, SOFIA Catheters, and BOBBY Balloon Guide Catheter. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received responses from Scafford Serron, Ph.D., VP of Global Quality dated June 16, 2022, July 18, 2022, and August 18, 2022, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations.\n\nThese violations include, but are not limited to, the following:\n\n1. Failure to verify a process that cannot be fully verified by subsequent inspection and test with a high degree of assurance and approved according to established procedures. The validation activities and results, including the date and signature of the individual(s) approving the validation and where appropriate the major equipment validated, shall be documented, as required by 21 CFR 820.75(a) – Process Validation. For example:\n\na. The catheter wash limitation process justifications (b)(4) dated October 31,2018 and (b)(4) dated June 10, 2021, do not specify the requirements for the catheter wash process validation prior to conducting the process validation. Additionally, the justifications provided for several test parameters do not provide a high degree of assurance and were not approved according to established procedures. Prior to the 2018 validation, this process had not been validated according to established procedures. Therefore, it is unknown if the catheter wash process sufficiently removes foreign material from the manufacturing process.\n\nThe responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm initiated CAPA(b)(4) to address Observation 1 and identified four root causes and training corrective actions, and conducted a retrospective review of processes requiring validation. Documents gathered at the inspection, “(b)(4)” (b)(4) and (b)(4), and provided in the response, “(b)(4)” (b)(4) require biocompatibility testing comply with ISO 10993-1. However, CAPA(b)(4) does not provide a high degree of assurance, as addressed in the FDA-recognized standard ISO-10993 [Biocompatibility]. For example:\n\ni) Per Part 1 of ISO-10993, a gap analysis and selection of biological endpoints for assessment is necessary to assess the biological safety of the medical device. The proposed responses and corrective actions do not address all biological endpoints, including pyrogenicity.\n\nii) Per Part 5 of ISO-10993, cytotoxicity testing standards require that the cytotoxicity be addressed at 24 hours and 48 hours, and that the results after 48 hours be less than or equal to Grade 2 by quantitative methods. The proposed responses and corrective actions incorrectly state the acceptance criteria to be, “Non cytotoxicity response with a test score of ≤2 at 24-Hour observation.”\n\niii) The validation process and corrective actions fail to address the residual sterilant levels after the changed catheter wash procedure and device sterilization. Per ISO 10993-7, “A valid method of extraction and measurement shall be used to determine the amount of EO and, where necessary, ECH delivered to the patient.”\n\niv) The proposed corrective actions do not address design transfer for the software validation functionality testing, in which there is failure to ensure that the device design is correctly translated into production specifications, as required by 21 CFR 820.30(h).\n\nb. It cannot be verified from the non-equipment software test report: coating tracker software (b)(4) that the tasks requiring a specific number of repeats for validation were conducted for the required number of repeats per the protocol.\n\nThe responses dated June 16, 2022, July 18, 2022, and August 18, 2022 indicate that the root cause investigation is completed, additional review of all other previously completed non-equipment software production pertaining to the hydrophilic coating process were identified and are being implemented, and corrective actions are ongoing under CAPA(b)(4). The adequacy of the responses cannot be determined until the outstanding inadequacies with CAPA(b)(4) under Observation 01 are addressed.\n\n2. Failure to establish and maintain adequate procedures for implementing and maintaining corrective and preventive actions, as required by 21 CFR 820.100. For example:\n\na. Your firm’s Supplier Corrective Action Request (SCAR) Process (b)(4) requires that the firm open a SCAR “when it is determined that a supplier corrective action is need for an NCR” (Nonconformance Report). The FDA investigator collected examples of nonconformance reported quality problems where no SCAR was opened by your firm as required by its procedure. Additionally, because these corrective actions were taken as a result of these nonconformances outside of your firm’s corrective action procedures, no evaluation as to whether actions taken adversely affected the finished device was completed, nor were the corrections verified as effective, as required by 21 CFR 820.100(a)(4).\n\nThe responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm initiated CAPA(b)(4) to address Observation 5 and identified five root causes. Your firm updated its procedure, (b)(4) to provide clarification to its employees as to when a SCAR needs to be initiated. Your firm submitted documentation that supports training of its employees on the new procedure. Your firm states that it will ensure each corrective and preventive action is effective through the Verification of Effectiveness process, though it is not clear exactly how and when that will occur. Your firm initiated a 3-year retrospective review of supplier NCR events where SCARs were not initiated and plans to evaluate any adverse effects of these NCRs as part of the CAPA underway. This activity is scheduled to be completed at the end of October 2022. The adequacy of your firm’s responses will be evaluated after you submit clarification of your plan to ensure effectiveness of the implemented corrective actions and documentation to support that effectiveness when complete.\n\nb. Your firm’s CAPA system fails to identify “rejects” as nonconforming product and therefore misses all nonconforming product during the manufacturing process as a quality data input for the CAPA system, as required by 21 CFR820.100(a)(1). Without nonconforming product as a quality data input to the CAPA system, the ability to detect recurring quality problems is greatly diminished.\n\nThe responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm stated that its Quality Reporting procedure does require your firm to periodically review rejected material and that its employees “could” request a CAPA if they decided to based on that review. Your firm updated its CAPA procedure (b)(4) to include Reject data\u002Ftrend for consistent wording between its other relevant SOPs for Quality Reporting to be more clear that rejected material needs to be investigated as nonconforming product and that data needs to be fed into the CAPA system. Your firm stated that it has “made employees aware” and that effectiveness checks are planned to be completed by February 2023. It is not clear whether your firm has evaluated whether the periodic reviews of the rejected material historically have warranted an investigation. Information is needed to clarify whether a retrospective review has been completed or is planned.\n\n3. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements. The procedures shall address the identification, documentation, evaluation, segregation, and disposition of nonconforming product. The evaluation of nonconformance shall include a determination of the need for an investigation and notification of the persons or organizations responsible for the nonconformance. The evaluation and any investigation shall be documented, as required by 21 CFR 820.90(a). For example:\n\nDuring production and quality inspection, nonconforming product is identified as a “reject”. While rejected\u002Fnonconforming product is identified, documented, and segregated, the firm is not evaluating the nonconformance to determine the need for an investigation and notification of persons or organizations responsible for the nonconformance, as required by 21 CFR 820.90(a).\n\nThe responses dated June 16, 2022, July 18, 2022, and August 18, 2022 are not adequate. Your firm made initial corrections to several procedures and definitions to ensure that rejected nonconforming product during the manufacturing process is accurately captured, trended, and fed into its CAPA system. Part of the issue related to a high reject rate was due to material that was destroyed during testing being labeled as “reject” in addition to actual nonconforming product. Your firm implemented an IT solution to label those samples separately as “destroyed” instead of “reject”. Your firm states that it has notified its relevant employees of the definition and procedure change. Your firm states that it plans to conduct effectiveness checks for CAPA (b)(4) and included the planned evaluation and timeframe for doing so, with a completion date of February 2023. Your firm also mentions a “preventive” action that plans to look at other product lines and systems where “reject” is used as a product designation to ensure that they are not missing any other nonconforming product documentation. It is not clear whether this includes a retrospective review of previous rejected materials in an attempt to determine whether an investigation needs to be opened into those nonconforming product. The adequacy of your firm’s responses will be evaluated after you provide information clarifying whether a retrospective review of rejected product will occur to determine whether an investigation can or should be done at this time.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm's response should be sent to CDRHWarningLetterResponses@fda.hhs.gov, or if e-mail cannot be used:\n\nFood and Drug Administration - CDRH\u002FORP\u002FDRP2\n\nCDRH Regulatory Inspections and Audit Team, WO66-1434\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to CMS case # 472344 when replying.\n\nIf you have any questions about the contents of this letter, please contact: Lydia Glaw, PhD at lydia.glaw@fda.hhs.gov or 301-796-1456.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBram Zuckerman, M.D.\n\nDirector\n\nOffice of Cardiovascular Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nAmy Smith\n\n35 Enterprise, Aliso Viejo, CA US 92656","MicroVention Costa Rica S.R.L.","microvention-costa-rica-srl-643188-09302022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmicrovention-costa-rica-srl-643188-09302022","2026-10-26T08:09:24.922135+00:00","Closed Out","2023-02-07","643188","2025-11-17","Charlie Noel","2026-08-20T01:16:19.813+00:00","VIA Electronic Mail","2022-09-30",{"id":75,"raw":76,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":86,"fei_number":19,"letter_url":87,"updated_at":88,"action_type":22,"case_status":23,"posted_date":89,"marcs_cms_no":90,"product_type":91,"closeout_date":19,"issuing_office":80,"recipient_name":92,"body_fetched_at":93,"delivery_method":94,"recipient_title":19,"reference_number":19,"action_taken_date":95,"medical_device_id":19,"response_letter_date":19},1996,[77,78,79,80,81,13,13,13],"\u003Ctime datetime=\"2023-07-18T04:00:00Z\">07\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-10T04:00:00Z\">07\u002F10\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchean-industries-dominicana-srl-660107-07102023\">Chean Industries Dominicana S.R.L. \u003C\u002Fa>","Center for Food Safety and Applied Nutrition","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Daniel C. Chean\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u002FCo-Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Chean Industries Dominicana S.R.L. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>19911 58th Ave., 1 FL\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Flushing\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11365\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dchean@gmail.com\"> dchean@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:el.siscador258@gmail.com\"> el.siscador258@gmail.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 10, 2023\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Reference #660107\u003C\u002Fp>\u003Cp>Dear Mr. Daniel C. Chean:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted a foreign inspection of your seafood processing facility, Chean Industries Dominicana S.R.L., located at Calle 21 No. 3, De La Urbanización Los Girasoles Del Este, Santiago, Dominican Republic (the) 51000 on February 28 - March 01, 2023. During the inspection, we found that you had serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). That inspection resulted in FDA’s issuance of an FDA-483, Inspectional Observations, listing the deviations found at your firm at the conclusion of the inspection.\u003C\u002Fp>\u003Cp>In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your dried sea cucumbers products are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation, and the 4th Edition of the Fish and Fisheries Products Hazards &amp; Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>Your significant deviations are as follows:\u003C\u002Fp>\u003Cp>1. You must conduct or have conducted for you a hazard analysis for each kind of fish and fishery product that you produce to determine whether there are food safety hazards that are reasonably likely to occur, and you must have and implement a written HACCP plan to control any food safety hazards that are reasonably likely to occur, to comply with 21 CFR 123.6(a) and (b). Specifically, your firm does not have a HACCP plan for dried sea cucumbers to control the food safety hazards of environmental chemicals, and pathogenic bacterial growth and toxin formation due to time\u002Ftemperature abuse, specifically \u003Cem>Staphylococcus aureus (S. aureus)\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>2. You must have a HACCP plan that, at a minimum, lists the critical limits that must be met, to comply with 21 CFR 123.6(c)(3). A critical limit is defined in 21 CFR 123.3(c) as \"the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard.\" However, your firm’s “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step for dried sea cucumbers conducted at a temperature range of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C – \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C for \u003Cstrong>(b)(4)\u003C\u002Fstrong> days is not adequate to control pathogenic bacteria growth and toxin formation. Specifically, the critical limits (time and temperature parameters) do not ensure that the maximum finished product water activity (Aw) is 0.85 or below to control the food safety hazard of \u003Cem>Staphylococcus aureus (S. aureus)\u003C\u002Fem>. \u003Cstrong>(b)(4)\u003C\u002Fstrong> the product sufficiently to reduce the water activity to 0.85 or below is critical to obtaining a safe final product. This value is based on the minimum water activity for toxin formation of S. aureus. Achieving the above-mentioned water activity will also inhibit the growth of other microbiological hazards. FDA recommends that your firm establish the \u003Cstrong>(b)(4)\u003C\u002Fstrong> parameters utilizing a scientific validation study to ensure that the final product will consistently achieve a water activity of 0.85 or below. Once all the parameters are validated, the critical factors for achieving the established water activity of less than 0.85 should be included as Critical Limits in the HACCP plan.\u003C\u002Fp>\u003Cp>For additional guidance you may reference the Fish and Fishery Products Hazards &amp; Controls Guidance - June 2022 Edition at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F80637\u002Fdownload, Chapter 9 for Environmental Chemical Contaminants Including Pesticides and Chapter 12 Pathogenic Bacterial Growth and Toxin Formation (Other Than \u003Cem>Clostridium botulinum\u003C\u002Fem>) as a Result of Time and Temperature Abuse.\u003C\u002Fp>\u003Cp>3. You must maintain adequate sanitation control records that, at a minimum, document monitoring and corrections set out in 21 CFR 123.11(b), to comply with 21 CFR 123.11(c). However, your firm did not maintain sanitation control records that document monitoring and corrections of sanitation deficiencies for the safety of water that comes into contact with food or food contact surfaces, including water used to manufacture ice; condition and cleanliness of food contact surfaces; prevention of cross-contamination from insanitary objects; maintenance of hand washing, hand sanitizing, and toilet facilities; protection of food, food packaging material and food contact surfaces from adulteration; proper labeling, storage and use of toxic chemicals; control of employee health conditions; and exclusion of pests. Specifically, on March 1st, 2023, the investigator requested sanitation monitoring records and your firm only had a calendar of weekly cleaning with boxes to check off the general area that was cleaned (kitchen, \u003Cstrong>(b)(4)\u003C\u002Fstrong> room, patio) and the initials of the person that did the cleaning. Sanitation monitoring records must document the monitoring and corrections for each of the eight key sanitation control procedure items listed above.\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your HACCP plan for dried sea cucumbers, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert 16-120. This alert can be found on FDA’s web site at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_25.html.\u003C\u002Fp>\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation (21 CFR Part 123) and the current Good Manufacturing Practice Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117 Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Giselle Jordan, Compliance Officer, Office of Compliance, Division of Enforcement, Food Adulteration and Assessment Branch (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Giselle Jordan via email at: giselle.jordan@fda.hhs.gov. Please include reference #660107 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Ann M. Oxenham\u003Cbr>Director\u003Cbr>Office of Compliance\u003Cbr>Center for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Daniel C. Chean\n\nRecipient Title\n\nGeneral Manager\u002FCo-Owner\n\nChean Industries Dominicana S.R.L.\n\n19911 58th Ave., 1 FL\n\nFlushing, NY 11365\n\nUnited States\n\ndchean@gmail.com\n\nel.siscador258@gmail.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nJuly 10, 2023\nWARNING LETTER\nReference #660107\nDear Mr. Daniel C. Chean:\nThe United States Food and Drug Administration (FDA) conducted a foreign inspection of your seafood processing facility, Chean Industries Dominicana S.R.L., located at Calle 21 No. 3, De La Urbanización Los Girasoles Del Este, Santiago, Dominican Republic (the) 51000 on February 28 - March 01, 2023. During the inspection, we found that you had serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). That inspection resulted in FDA’s issuance of an FDA-483, Inspectional Observations, listing the deviations found at your firm at the conclusion of the inspection.\nIn accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your dried sea cucumbers products are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation, and the 4th Edition of the Fish and Fisheries Products Hazards & Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\nYour significant deviations are as follows:\n1. You must conduct or have conducted for you a hazard analysis for each kind of fish and fishery product that you produce to determine whether there are food safety hazards that are reasonably likely to occur, and you must have and implement a written HACCP plan to control any food safety hazards that are reasonably likely to occur, to comply with 21 CFR 123.6(a) and (b). Specifically, your firm does not have a HACCP plan for dried sea cucumbers to control the food safety hazards of environmental chemicals, and pathogenic bacterial growth and toxin formation due to time\u002Ftemperature abuse, specifically Staphylococcus aureus (S. aureus).\n2. You must have a HACCP plan that, at a minimum, lists the critical limits that must be met, to comply with 21 CFR 123.6(c)(3). A critical limit is defined in 21 CFR 123.3(c) as \"the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard.\" However, your firm’s “(b)(4)” step for dried sea cucumbers conducted at a temperature range of (b)(4)°C – (b)(4)°C for (b)(4) days is not adequate to control pathogenic bacteria growth and toxin formation. Specifically, the critical limits (time and temperature parameters) do not ensure that the maximum finished product water activity (Aw) is 0.85 or below to control the food safety hazard of Staphylococcus aureus (S. aureus). (b)(4) the product sufficiently to reduce the water activity to 0.85 or below is critical to obtaining a safe final product. This value is based on the minimum water activity for toxin formation of S. aureus. Achieving the above-mentioned water activity will also inhibit the growth of other microbiological hazards. FDA recommends that your firm establish the (b)(4) parameters utilizing a scientific validation study to ensure that the final product will consistently achieve a water activity of 0.85 or below. Once all the parameters are validated, the critical factors for achieving the established water activity of less than 0.85 should be included as Critical Limits in the HACCP plan.\nFor additional guidance you may reference the Fish and Fishery Products Hazards & Controls Guidance - June 2022 Edition at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F80637\u002Fdownload, Chapter 9 for Environmental Chemical Contaminants Including Pesticides and Chapter 12 Pathogenic Bacterial Growth and Toxin Formation (Other Than Clostridium botulinum) as a Result of Time and Temperature Abuse.\n3. You must maintain adequate sanitation control records that, at a minimum, document monitoring and corrections set out in 21 CFR 123.11(b), to comply with 21 CFR 123.11(c). However, your firm did not maintain sanitation control records that document monitoring and corrections of sanitation deficiencies for the safety of water that comes into contact with food or food contact surfaces, including water used to manufacture ice; condition and cleanliness of food contact surfaces; prevention of cross-contamination from insanitary objects; maintenance of hand washing, hand sanitizing, and toilet facilities; protection of food, food packaging material and food contact surfaces from adulteration; proper labeling, storage and use of toxic chemicals; control of employee health conditions; and exclusion of pests. Specifically, on March 1st, 2023, the investigator requested sanitation monitoring records and your firm only had a calendar of weekly cleaning with boxes to check off the general area that was cleaned (kitchen, (b)(4) room, patio) and the initials of the person that did the cleaning. Sanitation monitoring records must document the monitoring and corrections for each of the eight key sanitation control procedure items listed above.\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your HACCP plan for dried sea cucumbers, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert 16-120. This alert can be found on FDA’s web site at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_25.html.\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation (21 CFR Part 123) and the current Good Manufacturing Practice Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117 Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\nPlease send your reply to the Food and Drug Administration, Attention: Giselle Jordan, Compliance Officer, Office of Compliance, Division of Enforcement, Food Adulteration and Assessment Branch (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Giselle Jordan via email at: giselle.jordan@fda.hhs.gov. Please include reference #660107 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nAnn M. Oxenham\nDirector\nOffice of Compliance\nCenter for Food Safety and Applied Nutrition","Chean Industries Dominicana S.R.L.","chean-industries-dominicana-srl-660107-07102023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchean-industries-dominicana-srl-660107-07102023","2026-10-26T08:08:13.900415+00:00","2023-07-18","660107","Food & Beverages","Mr. Daniel C. Chean","2026-08-20T00:52:23.166+00:00","Via Express Delivery","2023-07-10",4,{"510k":98,"classification":99,"enforcement":100,"event":101,"event_backfill":102,"pma":103,"warning_letter":104},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]